Standard BioTools Inc. $LAB Stock Position Decreased by Pacific Capital Partners Ltd

Key Points

• Pacific Capital Partners Ltd reduced its stake in Standard BioTools Inc. by 12.7% during Q2, now holding approximately 1,375,000 shares worth $1,650,000.
• Insider transactions include the Director of Casdin Partners Master Fund acquiring 250,000 shares at $1.27, increasing their position by 0.41%.
• Standard BioTools has a consensus rating of "Hold" with an average target price of $1.55, reflecting recent rating adjustments from various analysts.

Pacific Capital Partners Ltd lessened its holdings in Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 12.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,375,000 shares of the company's stock after selling 200,000 shares during the quarter. Standard BioTools makes up about 1.5% of Pacific Capital Partners Ltd's holdings, making the stock its 22nd largest position. Pacific Capital Partners Ltd owned 0.36% of Standard BioTools worth $1,650,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of LAB. Northern Trust Corp increased its holdings in Standard BioTools by 9.3% in the fourth quarter. Northern Trust Corp now owns 2,875,160 shares of the company's stock valued at $5,032,000 after buying an additional 243,522 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Standard BioTools by 30.3% during the fourth quarter. Jane Street Group LLC now owns 236,833 shares of the company's stock worth $414,000 after purchasing an additional 55,019 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Standard BioTools by 20.3% during the fourth quarter. Bank of America Corp DE now owns 222,851 shares of the company's stock worth $390,000 after purchasing an additional 37,605 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Standard BioTools by 53.3% during the fourth quarter. Deutsche Bank AG now owns 258,241 shares of the company's stock worth $452,000 after purchasing an additional 89,781 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Standard BioTools by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 168,777 shares of the company's stock worth $295,000 after purchasing an additional 7,304 shares during the last quarter. Hedge funds and other institutional investors own 53.74% of the company's stock.

Standard BioTools Stock Up 0.4%

Shares of LAB traded up $0.01 during midday trading on Friday, hitting $1.42. The company had a trading volume of 1,087,465 shares, compared to its average volume of 1,680,772. The company's 50 day moving average price is $1.30 and its 200 day moving average price is $1.19. The stock has a market cap of $540.52 million, a price-to-earnings ratio of -4.42 and a beta of 1.29. Standard BioTools Inc. has a 52 week low of $0.92 and a 52 week high of $2.32.

Insider Buying and Selling at Standard BioTools

In related news, Director Casdin Partners Master Fund, L bought 100,000 shares of the company's stock in a transaction dated Tuesday, September 9th. The stock was bought at an average price of $1.29 per share, with a total value of $129,000.00. Following the transaction, the director owned 60,875,000 shares of the company's stock, valued at approximately $78,528,750. This trade represents a 0.16% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have bought 1,233,220 shares of company stock valued at $1,546,446. 23.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on LAB shares. Wall Street Zen raised Standard BioTools from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Cowen lowered Standard BioTools from a "buy" rating to a "hold" rating in a report on Wednesday, August 13th. Finally, TD Cowen downgraded shares of Standard BioTools from a "buy" rating to a "hold" rating and set a $1.55 target price for the company. in a research note on Wednesday, August 13th. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $1.55.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.